Abstract :Abstract
The challenges in discovery and development of small molecule drug has led to the emergence of antibody drug conjugates (ADCs) as an alternative for targeted cancer therapy. Over the past two decades, several antigens that have selective over expression on cancer cell surface have been identified and they have been exploited for tumor specific cargo delivery. Specific antibodies can be engineered to function as small molecule targeting ligand that can bind tightly to tumor cell’s over expressing the target antigen. The potential of ADCsrepresentsa novel class of cancer cell specific antigen targeted chemotherapy agent. ADCsthus represent a significant step forward in the war against cancer and personalized medicine.